(NasdaqGM:ATAI), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in […]

(NASDAQ:JG), SHENZHEN, China, Jan. 08, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today extended its congratulations to Knowledge Atlas Technology Joint Stock Company Limited, also known as Zhipu, on its successful listing on the Main Board

VarmX and Rentschler Biopharma expand collaboration from early development to lateâ€'stage and commercial manufacturing of VMX-C001 VMXâ€'C001 builds on strong regulatory momentum, including FDA Fast Track Designation and PMDA Phase 1 waiver, as it progresses toward a global Phase 3 trial Manufacturing will be transferred from Rentschler Biopharma site in Laupheim (Germany) to Milford, MA

(TSX-V:XGC), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that work has commenced on the recently acquired Pico Machay Gold Project (“Pico Machay” or the “Project”). Xali Gold has commenced field work with the initiation of community engagement in anticipation of

(NASDAQ:JSPR), 67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow

(TSX-V:BRW),(OTC US:BRWXF),(Other OTC:BRWXF),(Boerse Frankfurt – Freiverkehr:1XQ), MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company“) is very pleased to announce a maiden, open-pit Mineral Inferred Resource Estimate (“MRE“) of 52.2 million tonnes (“Mt“) grading 1.08% Li2O and 131ppm Ta2O5 for its wholly owned Mirage Project located

(NasdaqGM:RANI), – A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill(R) capsule versus subcutaneous injection – SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the

(TSX-V:SURG),(OTC US:SRGXF),(Other OTC:SRGXF),(Boerse Frankfurt – Freiverkehr:G6D2), Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to report results from its 2025 multidisciplinary drilling and field program at the 100%-owned Berg Project in central British Columbia. The program was designed to

(NASDAQ:IRD), – Multi-asset pipeline with significant targeted data readouts and milestones – – Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 – – Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment – – Corporate presentation at J.P. Morgan Healthcare Conference on Thursday, January 15, at 8:15

(NASDAQ:AMRN), DUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025 operational accomplishments, and outlined 2026 priorities in advance of business development and investor meetings in San Francisco